Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta
 (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.
Inclusion Criteria:

 -  Patients with dyspepsia or epigastric pain and endoscopically proven gastric and
 duodenal ulcers

 -  Required laboratory parameters and time limits (screening blood tests will be taken
 including hemoglobin, white blood cell count, random glucose, potassium, sodium,
 chlorine, creatinine, AST, ALT, bilirubin, and alkaline phosphatase)

 -  Age > 18 years

 -  A statement that all patients must have signed an informed consent form prior to
 registration in study

 Exclusion Criteria:

 -  Patients who had undergone surgery for ulcers

 -  History of hypersensitivity to drugs to be used in the study

 -  Women who are pregnant or lactating or intended to get pregnant during the study
 period